Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M203551200 on March 27, 2003

J. Biol. Chem., Vol. 278, Issue 23, 20555-20564, June 6, 2003
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/23/20555    most recent
M203551200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedron, T.
Right arrow Articles by Chaby, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedron, T.
Right arrow Articles by Chaby, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

TLR4-dependent Lipopolysaccharide-induced Shedding of Tumor Necrosis Factor Receptors in Mouse Bone Marrow Granulocytes*

Thierry Pedron {ddagger}, Robert Girard § and Richard Chaby ¶ ||

From the {ddagger}Unité de Pathogénie Microbienne Moléculaire, Unité INSERM U389, Institut Pasteur, 75015 Paris, §Lymphocyte Development, URA-1961 of the National Center for Scientific Research, Pasteur Institute, 75015 Paris, and the Endotoxin Group, UMR-8619 of the National Center for Scientific Research, University of Paris-Sud, 91405 Orsay, France

Received for publication, April 12, 2002 , and in revised form, February 28, 2003.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
We reported previously that bone marrow granulocytes respond to small amounts of enterobacterial lipopolysaccharide (LPS) via a CD14-independent and TLR4-mediated mechanism by de novo expression of an inducible receptor (CD14) and by down-modulation of a constitutive receptor (L-selectin). In this report we address another effect of LPS: the down-regulation of receptors for tumor necrosis factor-{alpha}. In mouse bone marrow cells (BMC), this down-regulation is detectable soon (20 min) after exposure of the cells to low levels (0.5 ng/ml) of LPS. This temperature-dependent effect is rather selective for LPS and requires the presence of a conventional lipid A structure in the LPS molecule and a functional TLR4 molecule in the cells. The down-modulation, due to a shedding of the receptors, is blocked by p38 MAPK inhibitors, by a furin inhibitor, and by three metalloproteinase inhibitors (BB-3103, TIMP-2, and TIMP-3). In contrast, inhibitors of MEK, protein kinase C, cAMP-dependent protein kinase, and kinases of the Src family do not block the shedding. Analysis of BMC from mice lacking tumor necrosis factor receptor-1 (CD120a–/–) or tumor necrosis factor receptor-2 (CD120b–/–) indicates that the LPS-induced shedding is specific for CD120b. Thus, exposure of BMC to LPS triggers a rapid shedding of CD120b via a protein kinase C- and Src-independent pathway mediated by p38 MAPK, furin, and metalloproteinase. The additive effects of furin and metalloproteinase inhibitors suggest that these enzymes are involved in parallel shedding pathways.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Two major cell types, the neutrophilic granulocyte and the monocyte/macrophage, are associated with susceptibility to infections (1). Both derive from granulocyte-type progenitor cells present in the bone marrow. Therefore, a better knowledge of the events following the interaction of bacterial lipopolysaccharide (LPS)1 with bone marrow granulocytes can help us to understand some of its in vivo effects. We have shown in a previous study (2) that granulocytes from the bone marrow of LPS-responsive mice express an inducible LPS-binding site on their cell surface after exposure in vivo or in vitro to nanomolar concentrations of LPS. This cell surface molecule was identified later as CD14 (3, 4). In contrast to this expression of a receptor, many surface markers are actually down-modulated after exposure of cells to LPS. This has been observed in macrophages with mannose receptors (5), scavenger receptors (6), interleukin 6 receptors (7), CSF-M receptors (8), and TNF-{alpha} receptors (TNF-R) (9). Concerning BMC, we found in a previous study (10) that LPS induced in these cells a marked down-regulation of TNF-R, in the absence of any direct binding of LPS to TNF-R.

Because TNF-{alpha} and its receptors play a prominent role in inflammation and in LPS-induced septic shock (11, 12), we considered that the mechanism by which LPS induces the down-regulation of TNF-R in BMC would deserve closer scrutiny. The two known TNF-{alpha} receptors CD120a (p55) and CD120b (p75) have gained wide interest because of their outstanding pattern of activities. On the level of individual cells, CD120a is involved in various aspects of innate immunity, for example by inducing death of pathogen-afflicted cells. At the multicellular level, CD120a contributes to lymphoid organ development and controls defense by coordinating the inflammatory process. At the level of the whole organism, it induces changes such as fever and elevation of acute-phase serum proteins. The extracellular domain of the TNF receptors contains membrane-proximal regions that render these molecules susceptible to shedding. The membrane form of the TNF-{alpha} cytokine has, like TNF receptors, an extracellular domain sensitive to the TNF-{alpha} convertase (TACE/ADAM-17), a transmembrane disintegrin metalloproteinase of the ADAM family of proteases (adamalysin). It has been shown that TACE can cleave a number of cell surface molecules, such as CD120b (the p75 TNF-R2), TGF-{alpha}, CD62-L (L-selectin) (13), IL-1 receptor II, CD120a (the p55 TNF-R1) (14), and the L1 adhesion molecule (15) and thus participates in inflammatory and pathological reactions.

However, other mechanisms of TNF-R down-regulation, which are not mediated by metalloproteinases, have been suggested, including shedding by serine proteases (16) or even internalization of the receptors (17).

To date, the nature and the specificity of the mechanism by which LPS down-regulates TNF-R in BMC have not been explored but are of uttermost interest because regulation of TNF-Rs can take part in the hematopoietic and differentiation events that occur in the bone marrow after infection with microorganisms containing LPS, and may be of critical importance for efficient host defense.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Animals and Cell Culture—C57BL/10 ScSn and C57BL/6 mice were purchased from Harlan (Gannat, France). C57BL/10 ScCr mice were a gift from Dr. Marina Freudenberg (Freiburg, Germany). Mice lacking TNF-{alpha} receptor-1 (CD120a–/–) (18) and TNF-{alpha} receptor-2 (CD120b–/–) (19) were backcrossed for 10 generations to C57BL/6 and kindly provided by Dr. Horst Bluethmann (Hoffmann-La Roche). C3H/HeOU and C3H/HeJ mice were bred at the Pasteur Institute (Paris, France). 8–10-Week-old female mice were used in all experiments. Bone marrow cells (BMC) were collected from mouse femurs. CM is RPMI 1640 (Sigma) containing 20 mM HEPES, 1 mM sodium pyruvate, 2 mM Lglutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin. FCS was from Invitrogen.

Lipopolysaccharides—The LPSs from the Re-595 mutant of Salmonella enterica serovar minnesota (LPS-Sm) and from the J5 mutant of Escherichia coli (LPS-Ec) were from Sigma. The LPSs from S. enterica serovar choleraesuis (LPS-Sc), from S. enterica serovar senftenberg (LPS-Ss), and from Bordetella pertussis (LPS-Bp), and the lipid A fraction of the latter, were prepared as described previously (20, 21). The LPSs from Rhizobium species Sin-1, Rhizobium galegae, and Rhizobium leguminosarum biovar trifolii 24AR were provided by Dr. R. W. Carlson (University of Georgia, Athens, GA).

Reagents—The synthetic furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (DAVLACK) was purchased from Bachem (Bubendorf, Switzerland). Cytochalasin B, MG132, GF109203X, PP2, K252a, H89, and KT5720 were from Calbiochem. Phenanthroline, leupeptin, PMA, cholera toxin (CT), N-tosyl-L-phenylalanine chloromethyl ketone (TPCK), N-tosyl-lysine chloromethyl ketone (TLCK), anti-goat IgG-peroxidase conjugate, and the goat anti-mouse soluble TNF receptor type II antiserum were from Sigma. SB202190, SB203580, U126, AG 126, sodium Bt2cAMP, and sodium 8-(4-chlorophenylthio)-adenosine-3':5'cyclic monophosphate (CPT-cAMP), were from Biomol (Plymouth, PA). The metalloproteinase inhibitor BB-3103 was from British Biotech Pharmaceutical (Oxford, UK), and the mouse recombinants TIMP-2 and TIMP-3 were from Oncogene Research Products (Boston, MA). The Mycobacterium smegmatis peptidoglycan (PGN) was a gift from Dr. A. Adam (Orsay, France). This water-soluble molecule (about 20 kDa) was isolated by lysozyme treatment of the delipidated bacteria and consisted of a tetramer of the {alpha}-N-acetyl-D-glucosamine-1,4-N-glycolylmuramic acid disaccharide carrying a heptapeptide and was linked, via a phosphodiester bridge, to a short (10 sugar units) arabinogalactan chain. The lipophosphoglycans m-LPG and d-LPG were gifts from Dr. Emanuela Handman and Dr. Salvatore J. Turco, respectively. Stock solutions of leupeptin, TC, TLCK, Bt2cAMP, and CPT-cAMP were prepared in apyrogenic water. TPCK was dissolved in ethanol, the furin inhibitor in methanol, and TIMP-2 in 50% glycerol in PBS. All other reagents were dissolved in Me2SO. Stock solutions were stored at–20 °C, and further dilutions were made into CM just prior to use.

Radiolabeled TNF-{alpha}—For radiolabeling of TNF-{alpha}, we used a modification of the method of Tejedor and Ballesta (22). Na125I (1 mCi) was added, in a conical polypropylene centrifuge tube, to a solution of rTNF-{alpha} devoid of stabilizing protein (1 µg, 10 µl) in 40 µl of phosphate buffer (0.1 M, pH 7.3). A solution of chloramine-T (66 µg/ml in the phosphate buffer) was prepared at the moment of use. Three aliquots (2 µl) of this solution were added at 2-min intervals. The reaction was allowed to proceed for an additional 5-min period and stopped by adding 20 µl of Na2S2O5 (2 mg/ml in phosphate buffer). The whole process was carried out at room temperature. Solutions of KI (50 µl; 10 mg/ml in water) and BSA (200 µl; 5 mg/ml in phosphate buffer) were then added. The solution was applied to a column of Sephadex G-10 (10 ml) equilibrated with a solution of BSA (5 mg/ml) in phosphate buffer. The filtration was carried out with the same solution. The first peak of radioactivity (elution volume: 3.5 to 4 ml), corresponding to 125I-TNF-{alpha} (1,5 x 108 cpm/µg), was stored at 4 °C until use.

Binding of Radiolabeled TNF-{alpha} to BMC—BMC were washed (by centrifugation for 5 min at 1000 x g) in CM, maintained for 30 min at 4 °C, and then incubated in triplicate for 15 h at 4 °C (5 x 106 cells in 100 µl of CM supplemented with 10% FCS) with 125I-TNF-{alpha} (0.5–10 ng in 100 µl). Similar results were obtained when incubations were carried out for only 2 h at 4 °C. The cells were then washed in 0.2 ml of PBS, 5% FCS and rewashed in 0.4 ml of PBS, 50% FCS, and the radioactivity of the cell pellets was measured in a gamma counter (Kontron MR 480 C).

SDS-PAGE Analysis of Shedded TNF-R and Derived Fragments— Cell supernatants of 2 x 107 BMC were cultured for 1 h at 37 °C with or without LPS-Sc (25 ng in 50 µl CM). Protease inhibitors were added, and the cell suspension was centrifuged first at 700 x g (10 min, 4 °C) to remove residual cells and further at 145,000 x g (60 min, 4 °C) to remove cell-released membrane vesicles (blebs). After dialysis (30 min) against distilled water, the supernatants (20 µl) were submitted, under reducing conditions, to electrophoresis on a 12% polyacrylamide slab gel in Tris glycine in the presence of SDS. Molecular mass (rainbow) markers were run in parallel. The gel was fixed in transfer buffer (20 mM Tris, 150 mM glycine, 20% methanol), and proteins were transferred onto an Immobilon-P membrane (Millipore, Bedford, MA) with a semi-dry blotting system at 40 mA for 75 min. The membrane was blocked (18 h at 20 °C) with 5% defatted milk in PBS and washed five times (1 h) with 0.1% Tween 20 in PBS. Bands were detected either with radiolabeled TNF-{alpha} or with an anti-TNF-R2 antiserum. In the first technique, the membrane was incubated (18 h, 20 °C) with 10 ml of 125I-TNF-{alpha} (1.7 x 107 cpm), washed extensively with 0.1% Tween 20 in PBS, and dried, and bands were visualized by autoradiography. In the second technique (Western blotting), the membrane was blocked (18 h at 20 °C) with 1% BSA in PBS, washed, and incubated (2 h, 20 °C) with the anti-TNF-R2 antibody (1:100 in PBS containing 1% BSA). The blots were washed with 0.1% Tween 20 in PBS and incubated for1hat20 °C with normal rabbit serum (1:100 in PBS containing 1% BSA). The blots were then rewashed and incubated for 1 h at 20 °C with a peroxidase-labeled rabbit anti-goat IgG antiserum (1:20,000 in 1% BSA and 2% non-fat milk in PBS). After extensive washings, sites with peroxidase activity were detected with the Supersignal West Pico chemiluminescent substrate (Pierce) according to the guidelines of the manufacturer. Molecular weight standards (ProSeive color protein markers) were from BioWhittaker (Rockland, ME). All other electrophoresis reagents, including autoradiography Hyperfilm MP, were from Amersham Biosciences.

Statistics—Student's t test was used for statistical analysis. A probability of p < 0.05 was considered significant.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Rapid Down-regulation of TNF-Rs Induced by LPS in BMC—We have shown in previous reports (2, 20) that very small amounts of LPS can induce the expression of CD14 within a few hours in BMC, in the absence of serum. We also reported that LPS induces in the same cells a down-modulation of the binding of TNF-{alpha} (10). To investigate further the features of the latter effect and compare them to the former, we examined the influence of five parameters: LPS concentration, time, temperature, presence of serum, and presence of accessory adherent cells. In a first experiment, BMC were exposed for 1 h at 37 °C to relatively high concentrations of LPS (0.1–10 µg/ml), in the presence or absence of fetal calf serum. The cells were then washed, and the binding of 125I-TNF-{alpha} to the TNF receptors (TNF-R) was analyzed. We observed a similar down-modulation of TNF-R in the presence or absence of serum (Fig. 1A). The effect was already optimal at the lowest concentration of LPS used (0.1 µg/ml). In a second experiment performed with a 1000-fold lower range of LPS concentration (0.1–10 ng/ml), and in the absence of serum, we found that a significant down-modulation of the binding of 125I-TNF-{alpha} occurs with as little as 0.5 ng/ml LPS (Fig. 1B). These results confirmed our previous finding of LPS-induced down-modulation of the binding of TNF-{alpha} and indicated that this LPS-induced effect does not require serum.



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 1.
Effect of LPS on the binding of radiolabeled TNF-{alpha} to BMC. Cells (1.5 x 106 in 0.5 ml of CM) were incubated for 1 h at 37 °C with different concentrations of LPS-Sc (A and B) in the presence or absence of fetal calf serum (A), or with a fixed (50 ng/ml) concentration of LPS-Sc (C and D) for different times at 37 °C (C), or for 1 h at the indicated temperatures (D). The cells were then washed, and binding of 125I-TNF-{alpha} was determined as described under "Experimental Procedures." Values represent the arithmetic mean ± S.D. from the mean of duplicate experiments.

 

The kinetics of this LPS effect appeared markedly more rapid than that of the LPS-induced expression of CD14 mentioned above; several hours are required for LPS-induced CD14 expression (20), whereas only 20 min of exposure to LPS allows a significant reduction of the binding of 125I-TNF-{alpha} (Fig. 1C). On the other hand, when the cells were exposed to LPS at 4 °C, there was no detectable down-modulation of TNF-R (Fig. 1D), thus indicating that rapid temperature-dependent reactions are involved. In all experiments, the LPS-induced decrease of TNF-{alpha} binding was always partial (40–60% decrease induced by 50–100 ng/ml S. enterica LPS). When the cells were exposed to LPS for longer periods (more than 90 min), a second phenomenon occurred, with a progressive increase of TNF-R expression leading, after a few hours, to a marked up-regulation of the receptor (data not shown). Because the first steps of the LPS-induced signaling cascade are of highest interest, this study was restricted to the earliest down-modulation phase of the response to LPS.

We also observed that the LPS-induced down-modulation of TNF-R still occurs after removal of B lymphocytes from the BMC population with magnetic beads coated with an anti-B220 antibody, or after removal of adherent cells by incubation for 3 h at 37 °C in plastic dishes (data not shown). In the following sections of this paper, all experiments have been performed with total BMC, and the cells have been exposed to LPS, or to other agents, for 1 h at 37 °C, in the absence of serum.

Specificity and TLR4 Dependence of the LPS-induced Down-modulation of TNF-R—Information on the specificity of the triggering agent for TNF-R down-modulation was obtained by comparison of the effects induced by the proper TNF-R ligand (TNF-{alpha}), and by several agents selected either because they represent major components exposed on the surface of different microorganisms (LPSs in Gram-negative bacteria, peptidoglycan in Gram-positive bacteria, and lipophosphoglycans in parasites) or because they can induce another response (CD14 expression) in BMC (cAMP derivatives and cholera toxin) (23). BMC were exposed to the agents and analyzed for their capacity to bind 125I-TNF-{alpha} as mentioned above. The results (Table I) show that TNF-{alpha}, the natural ligand of TNF-R, reduced the capacity of the cells to bind 125I-TNF-{alpha}. We will show further (end of the next paragraph) that this effect is not due to binding inhibition by the unlabeled ligand, but rather to an efficient down-regulation of the receptor. On the other hand, among various other agents tested, only LPSs or a lipid A fragment thereof exhibited a down-modulation effect. The polysaccharide fragments isolated from two Salmonella LPSs were inactive. It should be noted that cAMP derivatives and cholera toxin, which induce CD14 expression in BMC as efficiently as LPS (23), were both unable to down-regulate TNF-R in these cells (Table I).


View this table:
[in this window]
[in a new window]
  		TABLE I
Induction of TNF-R down-modulation by different agents

 

Toll-like receptor-4 (TLR4) is involved in several effects induced by LPSs of conventional structures (24). However, some LPS effects independent of TLR4 have been reported, such as induction of matrix metalloproteinase-9 (MMP-9, gelatinase) (25), production of Mn-superoxide dismutase (26), and induction of bacterial clearance (27). Therefore, it appeared important to determine whether the LPS-induced down-modulation of TNF-R was mediated or not by TLR4. In addition to normal C3H/HeOU mice, we used two mouse strains that have mutations on the Tlr4 gene as follows: the C3H/HeJ strain, which expresses non-functional TLR4 molecules, and the C57BL/10 ScCr strain, in which TLR4 is completely missing (28, 29). The results in Fig. 2 show that an LPS with a conventional lipid A structure (LPS-Sc) induced TNF-R down-regulation in BMC from C3H/HeOU mice but not in BMC from C3H/HeJ and C57BL/10ScCr mice. We also found that LPSs with atypical lipid A structures, such as those of Rhizobium species Sin-1, R. galegae, and R. leguminosarum biovar trifolii 24AR, reported previously (30) to induce CD14 expression in BMC by a TLR4-independent pathway, were unable to down-regulate TNF-R (data not shown). Taken together, these results clearly indicate that the LPS-induced down-modulation of TNF-R in BMC requires the presence of a conventional lipid A structure in the molecule and the presence of a functional TLR4 molecule in the cells.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 2.
Comparison of the effect of LPS on the binding of TNF-{alpha} in BMC from different mouse strains. BMC (1.5 x 106 in 0.5 ml CM) from normal (•) or TLR4-deficient ({circ} and {triangleup}) mice were incubated for 1 h at 37 °C with different concentrations of LPS, in the absence of serum. The cells were then washed, and their capacity to bind 125I-TNF-{alpha} was determined as in Fig. 1. Values represent the arithmetic mean ± S.D. from the mean of duplicate experiments. Two independent experiments gave similar results.

 

Absence of LPS-induced Internalization of TNF-R—Cell surface molecules can be down-modulated by internalization or by shedding. To determine whether LPS-induced TNF-R down-modulation could be due to internalization, we used an inhibitor of cytoskeleton-dependent internalization, cytochalasin B. In a preliminary experiment, internalization of Fc receptors (FcR) was use as a model to evaluate the efficiency of cytochalasin B as an inhibitor of internalization in BMC. The cellular density of FcR was estimated by determining the specific binding of 125I-labeled immunoglobulins at 4 °C (binding inhibitable with a large excess of unlabeled ligand). We found that in conditions where shedding is blocked (in the presence of 5 mM phenanthroline), incubation of the cells at 37 °C for 1 h induced an internalization of 93% of FcR, and 48.4% of that internalization was inhibited in the presence of 10 µg/ml cytochalasin B. Because this compound is not cytotoxic for BMC at the concentration used (as assessed by the absence of propidium iodide incorporation), it can be concluded that, as already observed in other cell types (31), cytochalasin B efficiently inhibits internalization processes in BMC. We then examined the influence of cytochalasin B on LPS-induced TNF-R down-modulation. We found that the down-modulation of TNF-R induced by 50 ng/ml of LPS was 54 ± 1% in the absence of cytochalasin B and 46 ± 1% in the presence of cytochalasin B. This moderate effect of the inhibitor indicates that the large majority (85%) of the LPS-induced down-modulation of TNF-R is not attributable to internalization.

Influence of Protease Inhibitors—To evaluate the second possible hypothesis consisting of a shedding of the receptors, we analyzed the effects of several protease inhibitors. The concentration at which each inhibitor was used was selected on the basis of its cellular effect reported in the literature or previously obtained with BMC in our laboratory. The protease inhibitors were not cytotoxic at the concentration used, as assessed by the absence of incorporation of propidium iodide, determined by FACS analysis. Among the four inhibitors tested, we found that two serine protease inhibitors (TLCK and TPCK) induced a marked reduction of the LPS effect (Table II). On the other hand, MG-132 and leupeptin (inhibitors of proteasome and serine/cysteine proteases, respectively) were ineffective.


View this table:
[in this window]
[in a new window]
  		TABLE II
Effect of protease inhibitors on LPS-induced down-modulation of TNF-R

 

The marked effect of the serine protease inhibitors, particularly TPCK, indicated that a proteolytic step is involved in TNF-R down-modulation. We examined whether TPCK can block in the same cells the down-modulation of another marker, CD16. By FACS analysis with a specific fluorescent antibody, we established in a preliminary experiment that a 27% down-modulation of CD16 occurs in BMC exposed to 100 ng/ml PMA for 1 h at 37 °C. When we examined the effects of TPCK, we found that at a concentration of 20 µM, it inhibited 90% of the LPS-induced down-modulation of TNF-R, and only 9% of the PMA-induced down-modulation of CD16. This suggests that in BMC the proteolytic step involved in LPS-induced down-modulation of TNF-R is not a common step involved in all down-modulation effects.

Influence of Metalloproteinase Inhibitors—Because proteolysis can lead to receptor shedding, and because shedding is often due to metalloproteinases, we examined the influence of metalloproteinase inhibitors. We first observed that 5 mM 1,10-phenanthroline, a metalloproteinase inhibitor of relatively broad specificity, markedly reduced (74 ± 9%) the LPS-induced down-modulation of TNF-R. The involvement of a metalloproteinase was confirmed by the use of a second metalloproteinase inhibitor, BB-3103. This compound is more selective than phenanthroline and inhibits a more restricted group of metalloproteinases, including TACE. We found (Fig. 3A) that BB-3103 induced a clear inhibition (33%) of the LPS effect. Inhibition by BB-3103 was statistically significant at the three concentrations used (at 25 µM, p = 0.0009 in a Student's t test).



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 3.
Influence of metalloproteinase inhibitors on induced down-modulations of TNF-R. BMC (1.5 x 106 in 0.5 ml of CM) from C3H/HeOU mice were incubated first (30 min, 37 °C) with the metalloproteinase inhibitors BB-3103 (A), TIMP-2, or TIMP-3 (B) and were then exposed for 1 h at 37 °C to LPS (50 ng/ml) (A, black bars, B) or TNF-{alpha} (20 ng/ml) (A, hatched bars), in the presence of the inhibitors. TNF-R down-modulation induced by LPS or TNF-{alpha} is expressed as the percentage of decrease of bound 125I-TNF{alpha}. Values represent the arithmetic mean ± S.D. from the mean of duplicate experiments. Three independent experiments gave similar results.

 

Because TNF-{alpha} can also induce a down-modulation of TNF-R (Table I), we compared the effects of BB-3103 on TNF-{alpha}- and LPS-induced down-modulations. We found that BB-3103 did not inhibit the TNF-{alpha}-induced effect (Fig. 3A). The same absence of inhibition was observed in cells from C3H/HeJ mice (data not shown). Therefore, the metalloproteinase involved in the TLR4-dependent down-modulation induced by LPS (sensitive to BB-3103) is different from the metalloproteinase involved in the TLR4-independent down-modulation induced by TNF-{alpha}, which is insensitive to BB-3103 but sensitive to phenanthroline (data not shown).

In addition to synthetic inhibitors, it appeared important to examine the effect of physiologic inhibitors of metalloproteinase, belonging to the group of tissue inhibitors of matrix metalloproteinases (TIMPs). Among the different TIMPs, it was particularly important to test TIMP-2 because, unlike TIMP-1 and TIMP-3, no inhibition of ADAMs by TIMP-2 has been reported so far. The results in Fig. 3B show that TIMP-2 induced a significant but quite minor (20%) inhibition of the LPS-mediated down-regulation of TNF-R. This supports the notion that matrix metalloproteinases (MMPs) play only a marginal role in this LPS effect. We also examined the effect of TIMP-3, which is known to inhibit ADAM17 (TACE) quite well. We found again that the inhibition of the LPS effect was rather low (20%) and similar to that obtained with TIMP-2 (Fig. 3B).

TNF-R Down-regulation Is Due to the Shedding of Receptor Fragments—The absence of internalization, and the blocking effect of protease and metalloproteinase inhibitors, suggested that TNF-R down-modulation was due to an enzymatic cleavage. Therefore, we looked for the presence of a soluble form of TNF-R in the cell culture supernatant of LPS-treated cells. BMC from C3H/HeOU mice were exposed to 50 ng/ml LPS for 1 h at 37 °C. The capacity of the culture supernatant to inhibit the binding of 125I-TNF-{alpha} at 4 °C was then examined. For comparative purposes, we used the culture supernatant of an untreated cell, in which LPS was added at the same concentration (50 ng/ml). In an experiment carried out on five replicates of undiluted culture supernatants, we observed with culture supernatants of LPS-treated cells an inhibition of 125I-TNF-{alpha} binding (52 ± 4%) significantly higher (p = 0.002 in a Student's t test) than the effect of supernatants from untreated cells (37 ± 4%). This inhibition was observed in the cold (4 °C), suggesting that it was independent of cellular metabolism.

We also analyzed more directly the shedded components that were able to interact with TNF-{alpha}. Culture supernatants of BMC from C3H/HeOU mice, exposed to LPS or to medium alone, were analyzed by SDS-PAGE after removal of membrane blebs by centrifugation at 145,000 x g for 1 h. TNF-R or derived fragments with TNF binding capacity were detected with 125I-TNF-{alpha}. Three components (59, 52, and 41 kDa) with TNF binding capacity were detected in the supernatant of BMC exposed to LPS and were not detectable in LPS-untreated cells (Fig. 4B). These components were clearly distinct from the two major intact TNF receptors (bands at 55 and 78 kDa) detected in a 1% Triton X-100extract of LPS-untreated BMC (Fig. 4A). Taken together, this result and that mentioned above show that three fragments of TNF-R are shed from the cell surface upon exposure to LPS and retain the capacity to bind 125I-TNF-{alpha} and to block the binding of this cytokine to its cellular receptors. In addition, the shedding of a 59-kDa fragment, which cannot occur from the 55-kDa membrane TNF-R1, strongly suggests that TNF-R2 is at least partially cleaved during incubation of the cells with LPS. These results are reminiscent of those obtained with other activated cell types; for example, T cells activated with phorbol ester and calcium ionophore release a soluble 40-kDa fragment of the extracellular domain of TNF-R2 (32), and polymorphonuclear leukocytes exposed to the chemotactic peptide N-formyl-Met-Leu-Phe release a 43-kDa fragment of TNF-R2 (33).



View larger version (35K):
[in this window]
[in a new window]
  		FIG. 4.
SDS-PAGE analysis of shedded TNF-binding molecules. BMC (2 x 107) from C3H/HeOU mice were either extracted with 1% Triton X-100 (1 h, 4 °C) in the presence of protease inhibitors or incubated for 1 h at 37 °C with or without LPS-Sc (50 ng/ml). Protease inhibitors were added to the cell cultures. Insoluble material was removed from extracts and cell culture supernatants by centrifugation (1 h, 4 °C) at 10,000 x g, and 145,000 x g, respectively. After dialysis against distilled water, membrane extracts (A) and cell culture supernatants (B) were analyzed by 12% SDS-PAGE and blotting onto an Immobilon-P membrane. Bands were detected by autoradiography after incubation (18 h, 20 °C) with 125I-TNF-{alpha} (1.7 x 107 cpm).

 

Influence of a Furin Inhibitor—The above results suggest that exposure to LPS activates a metalloproteinase involved in the shedding of TNF-R. Most metalloproteinases are regulated through a cysteine-switch mechanism that requires pro-domain removal for the protease to become active. This processing is essentially mediated by serine endoproteinases among which furin is the best characterized. This calcium-dependent transmembrane enzyme of the subtilisin family can process proteins containing the recognition motif RXKR. In an attempt to clarify the putative implication of furin in the LPS-induced shedding of TNF-R, we treated BMC with increasing concentrations of the synthetic furin inhibitor decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone (DAVLACK), and we examined the ability of these cells to shed TNF-R after exposure to LPS. Because the furin inhibitor was dissolved in methanol for the preparation of the stock solution (10 mM; 7.44 mg/ml), we also examined the influence of the corresponding doses of methanol on the shedding effect. The results (Fig. 5) show that methanol alone had a marginal effect, whereas the furin inhibitor induced a marked dose-dependent inhibition of the TNF-R shedding triggered by LPS. This finding was somewhat unexpected because furin is considered as a constitutively active protease. One explanation of this effect of the furin inhibitor could be that the enzyme involved in TNF-R shedding has a short half-life so that shedding would require continuous processing by furin to regenerate an active form of the "sheddase." A second possibility could be that a yet unidentified serine protease sensitive to the furin inhibitor (a furin-like serine protease) was activated by LPS and played a direct role in cleaving TNF-R.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 5.
Influence of a furin-like protease inhibitor. BMC (1.5 x 106 in 0.5 ml of CM) from C3H/HeOU mice were incubated first (30 min, 37 °C) with different concentrations of the furin inhibitor or of its solvent (methanol) and were then exposed for 1 h at 37 °C to LPS (50 ng/ml). The cells were then washed and their capacity to bind 125I-TNF-{alpha} was determined as in Fig. 1. Values represent the arithmetic mean ± S.D. from the mean of triplicate experiments. Three independent experiments gave similar results.

 

Additive Effects of Furin and Metalloproteinase Inhibitors— Because inhibitions by furin or metalloproteinase inhibitors were always incomplete, it appeared important to combine different inhibitors in order to determine whether different "sheddases" are activated by LPS and whether this activation occurs by sequential (dependent) or parallel (independent) pathways. We used the metalloproteinase inhibitor BB-3103, the two tissue inhibitors of MMP mentioned above (TIMP-2 and TIMP-3), and the furin inhibitor (DAVLACK), alone or combined by pairs, at the minimal concentration at which optimal inhibitions occur. The results (Fig. 6) show that inhibitions of the LPS effect by mixtures of BB-3103 and TIMP-2 (46%) or TIMP-3 (58%) were not significantly different from the inhibition obtained with BB-3103 alone (52%). In contrast, combinations of the furin inhibitor DAVLACK and one of the three metalloproteinase inhibitors produced nearly additive inhibitions, as compared with the effects of a single compound. This is particularly clear with DAVLACK and BB-3103, which produced 64 and 52% inhibition, respectively, when used separately and 94% inhibition when used together. This result suggests that two independent pathways, mediated by a metalloproteinase and a furin, may concur to the LPS-induced shedding of TNF-R.



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 6.
Influence of combinations of inhibitors. BMC (1.5 x 106 in 0.5 ml of CM) from C3H/HeOU mice were incubated first (30 min, 37 °C) with a single inhibitor or a combination of two inhibitors: TIMP-2 (0.2 µg/ml), TIMP-3 (0.2 µg/ml), BB-3103 (25 µM), and the furin inhibitor DAVLACK (100 µM). LPS (50 ng/ml) was then added, and the cells were reincubated for 1 h at 37 °C in the presence of the inhibitors. TNF-R down-modulation induced by LPS is expressed as the percentage of decrease of bound 125I-TNF-{alpha}. Values represent the arithmetic mean ± S.D. from the mean of triplicate experiments. Four independent experiments gave similar results.

 

Role of Protein Kinases—To analyze the signaling mechanisms involved in the shedding induced by LPS, we examined the influence of various protein kinase inhibitors. Again, the concentration at which each inhibitor was used was selected on the basis of literature data and of previous observations obtained with BMC in our laboratory (4, 34). For example, we found in preliminary experiments that 25 µM SB203580, SB202190, and U126 markedly reduced the LPS-induced expression of CD14 in BMC (69, 84, and 88% inhibition, respectively). We also checked that the protein kinase inhibitors were not cytotoxic at the concentration used (absence of propidium iodide incorporation determined by FACS). BMC were then incubated at 37 °C with the inhibitors, and LPS (50 ng/ml) was added 30 min later. After 90 min at 37 °C, the cells were washed and analyzed for their capacity to bind 125I-TNF-{alpha} at 4 °C. We found that a number of kinase inhibitors did not modify significantly the LPS-induced effect. This was particularly the case with inhibitors of serine/threonine kinases, PKC, cAMP-dependent protein kinase, protein-tyrosine kinase, and an inhibitor of the MAP kinase MEK (Table III). In contrast, two inhibitors of the p38 MAPK (SB202190 and SB203580) inhibited efficiently the response to LPS (Fig. 7). SB203580 was active at lower doses than SB202190.


View this table:
[in this window]
[in a new window]
  		TABLE III
Influence of various kinase inhibitors on LPS-induced down-modulation of TNF-R

 


View larger version (16K):
[in this window]
[in a new window]
  		FIG. 7.
Influence of inhibitors of p38 MAPK. BMC (1.5 x 106 in 0.5 ml of CM) from C3H/HeOU mice were incubated first (30 min, 37 °C) with different concentrations of SB202190 (•) or SB203580 ({circ}) and were then exposed for 1 h at 37 °C to LPS (50 ng/ml). The cells were then washed, and their capacity to bind 125I-TNF-{alpha} was determined as in Fig. 1. Values represent the percentage of LPS-induced down-modulation in the presence of the agents and are the arithmetic mean ± S.D. of triplicate experiments. Three independent experiments gave similar results.

 

Other kinases that may be involved in the LPS effect are Src kinases, a family of protein-tyrosine kinases that binds to components of the focal adhesion complex. Contradictory data have been reported concerning the role of these kinases in LPS signaling. On one hand, several lines of evidence suggested that lethal effects of LPS, and activation of monocytes and macrophages by LPS, involve the activation of protein-tyrosine kinases of the Src family (35, 36, 37). On the other hand, Meng and Lowel (38) established that LPS induces macrophage activation in the absence of the Src family kinases Hck, Fgr, and Lyn. To determine whether kinases belonging to that family are involved in the LPS-induced shedding of TNF-R in BMC, we used PP2, a potent and selective inhibitor of Src kinases (39). The results (Table III) indicated that PP2 did not block the TNF-R shedding induced by LPS.

We also examined the influence of activators and inhibitors of PKC. It has been reported that phorbol 12-myristate 13-acetate (PMA), a known PKC activator, can induce the down-modulation of various receptors (40). We found, however, that 100 ng/ml PMA did not induce a down-regulation of TNF-R and did not inhibit the shedding induced by LPS (data not shown). This shedding was not inhibited either by GF109203X, a selective inhibitor of PKC. Therefore, these results indicate that PKC is not involved in the LPS-induced shedding of TNF-R.

Comparison of TNF-R Shedding in CD120a–/– and CD120b–/– Mice—The results described above do not indicate whether the two known receptors for TNF-{alpha}, TNF-R1 (CD120a) and TNF-R2 (CD120b), are both down-regulated upon stimulation with LPS or whether the shedding is restricted to one of the receptors. To address this question we compared BMC of CD120a–/– and CD120b–/– mice to those of normal animals. We found that prior to LPS exposure, the amount of TNF-binding sites on CD120b-deficient cells was, as expected, markedly lower than that of cells from wild type animals (binding of 125I-TNF-{alpha} was of 7300 ± 970 cpm with CD1206–/– cells and 11,770 ± 760 cpm with normal cells). In contrast, in CD120a-deficient cells, the inability to produce this receptor is compensated by an overexpression of the second receptor, leading to an overall binding (13,600 ± 700 cpm) slightly higher than that found in wild type cells. After exposure of the cell from the three different origins to LPS, very clear-cut results were obtained (Fig. 8). The shedding of TNF-R was significantly increased in cells from CD120a–/– mice as compared with that of cells from wild animals, whereas no significant shedding could be detected in BMC from CD120b–/– mice. This result indicates that LPS induces a shedding of CD120b but cannot down-regulate CD120a. The results also show that the incomplete shedding of TNF-{alpha} receptors observed in normal mice is not exclusively due to the concomitant presence of cleavable (CD120b) and uncleavable (CD120a) molecules on their cell surface because in CD120a–/– animals, which express exclusively CD120b, the shedding of this receptor, although higher than in wild animals, remains incomplete.



View larger version (10K):
[in this window]
[in a new window]
  		FIG. 8.
Comparison of TNF-R shedding in wild and TNF-R knockout mice. BMC (cells pooled from five mixed sex animals) from wild C57BL/6 mice and from CD120a–/– or CD120b–/– animals of the same genetic background (1.5 x 106 cells in 0.5 ml of CM) were incubated (1 h at 37 °C) with or without LPS-Sc (50 ng/ml) in the absence of serum. The cells were then washed, and their capacity to bind 125I-TNF-{alpha} was determined as in Fig. 1. Without exposure to LPS, the binding of 125I-TNF-{alpha} was of 11,700 ± 760, 13,600 ± 700, and 7300 ± 970 cpm, respectively. Down-modulation induced by LPS was the percentage of decrease of bound 125I-TNF-{alpha}. Values represent the arithmetic mean ± S.D. of triplicate experiments in one representative experiment. Three independent experiments gave similar results.

 

The presence of the fragments of 59, 52, and 41 kDa detected above (Fig. 4) in the supernatant of BMC from wild mice was further analyzed in the supernatants of CD120a–/– and CD120b–/– cells exposed to LPS. Cell culture supernatants were analyzed by 12% SDS-PAGE. After blotting onto an Immobilon-P membrane, CD120b (TNF-R2) and derived fragments were analyzed with an anti-TNF-R2 antiserum. The results in Fig. 9 show that exposure to LPS enhanced the intensities of the 52- and 41-kDa proteins in supernatants of CD120a–/– cells, whereas no enhancement was observed in CD120b–/– cells. In contrast, the 59-kDa fragment was not detected by the anti-TNF-R2 antibody.



View larger version (39K):
[in this window]
[in a new window]
  		FIG. 9.
SDS-PAGE analysis of TNF-R shedding in TNF-R knockout mice. BMC (2 x 107) from CD120a–/– or CD120b–/– mice were incubated for1hat37 °C with or without LPS-Sc (250 ng/ml). Cell culture supernatants were analyzed by 12% SDS-PAGE. After blotting onto an Immobilon-P membrane, the bands were detected as described under "Experimental Procedures" by Western blotting with an anti-TNF-R2 antiserum.

 


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Our efforts to elucidate the mechanisms of various responses of BMC to LPS led us to examine, in previous studies, the expression of CD14 and, in this study, the down-modulation of TNF-Rs. Expression of CD14 in BMC is a rather slow response (requiring several hours) that can be induced by low concentrations of LPS but also by various other agents such as TNF-{alpha} (10), staurosporine (3), cholera toxin, and cAMP analogs (23). A similar response to LPS and TNF-{alpha} can also be observed in macrophages (41). In contrast, the experiments described herein show that in BMC the shedding of TNF-R induced by LPS is a rather rapid and specific response. It requires less than 30 min and cannot be triggered by other activators of BMC, such as the CD14 inducers cholera toxin and cAMP analogs. Furthermore, unlike observations carried out in vivo and showing that C3H/HeJ mice respond to LPS by shedding TNF-R (42), we found that in vitro, there was no shedding of TNF-R in response to enterobacterial LPS, in BMC from TLR4defective mice (C3H/HeJ and C57BL/10 ScCr).

Other agents, such as phorbol esters, are also known to induce the shedding of various cell surface molecules (40). For example, both LPS and PMA down-modulate TNF-R in macrophages (43, 44). However, the mechanisms by which LPS and PMA trigger shedding can depend considerably on the cell type. Indeed, it has been shown that in THP-1 cells, PMA activates a shedding of TNF-{alpha}, whereas LPS does not (45). In contrast, we observed here that in BMC, LPS induced a down-modulation of TNF-R, whereas PMA did not.

The sensitivity of the LPS-induced shedding of TNF-R to metalloproteinase inhibitors strongly suggests that like the majority of receptors in various cell types, the TNF-{alpha} receptors in BMC are probably cleaved by a metalloproteinase after activation of the cells with LPS. In most cases, shedding leading to the solubilization of the functional ectodomains of cell surface proteins is due to members of the ADAM family of metalloproteinases. These sheddases contain both metalloproteinase and disintegrin (integrin-binding) domains. Three members of this family have been particularly studied: ADAM-17, ADAM-10, and MDC9 (46, 47, 48). ADAM-17, also known as TNF-{alpha}-converting enzyme (TACE), appeared first as a good candidate for the LPS-induced shedding of TNF-R in BMC, because this effect was blocked by BB-3103 which is known to inhibit TACE with good selectivity (49), and because TACE is involved in the shedding of the two TNF-Rs (CD120a and CD120b) induced by PMA in other cell types (13, 14). However, two established features of TACE do not fit with our observations. First, TACE is PKC-regulated (50), and second, TACE-induced shedding of TNF-R is generally activated by PMA (14). Therefore, the failure of a PKC inhibitor to block LPS-induced shedding of TNF-R (Table III) and the failure of PMA to down-regulate TNF-R in BMC suggest that in this cell type TACE may not be involved in the LPS-induced shedding of TNF-R. This conclusion is also confirmed by the observation that TIMP-3, a good inhibitor of TACE, induced only a moderate inhibition of this LPS effect.

Shedding by other members of the metalloproteinase disintegrin family cannot be excluded. At least 23 ADAMs have been identified to date. ADAM-10 (the mammalian homolog of Kuz-banian) and ADAM-9 (MDC9, meltrin-{gamma}) belong to this family. Involvement of ADAM-9 in the shedding of TNF-R is unlikely because the specificity of ADAM-9 is very different from that of TACE (48). Concerning ADAM-10, it has been shown that processing of the transmembrane protein Notch by this disintegrin is neither augmented by PMA nor regulated by PKC (51). These features are very similar to those of the LPS-induced shedding of TNF-R. A second reported example of a shedding that is not up-regulated by phorbol esters is the cleavage of HER2, a tyrosine kinase receptor that is overexpressed in breast cancer (52). The metalloproteinase involved in this shedding is as yet unidentified.

Another important branch of the superfamily of metalloproteinases is represented by the zinc-dependent family of MMPs (53). TIMPs are sometimes used to determine whether a shedding process is ADAM- or MMP-dependent. However, TIMP-1 and TIMP-3 also inhibit ADAM-10 (54), and TIMP-3 inhibits ADAM-12 and ADAM-17 (TACE) (55). Our observation that TIMP-2, which has no reported activity against ADAMs, induces a partial inhibition of the LPS-mediated shedding of TNF-R2 suggests that a fraction of this shedding (about 20%) may be due to an MMP. The ability of this MMP to be regulated by LPS suggests that it might be a membrane-type MMP, such as MT1-MMP or MT4-MMP, which are both inhibited by TIMP-2 (56) and contain a furin-susceptible site (53). However, the contribution of this metalloproteinase in the total shedding is only partial, and cleavage of TNF-R likely depends also on another enzyme.

In this regard, we found that TLCK and TPCK, two inhibitors of serine proteases, inhibited very efficiently the LPS-induced shedding of TNF-R. This can probably be ascribed to an indirect maturation role of serine proteases on sheddases. Indeed, these metalloproteinases are themselves targets of proteolytic events that can either strip off their catalytic domain or allow their maturation to an active form. In this regard, it has been suggested that matrix metalloproteinases and ADAM proteases are synthesized with a prodomain that blocks their catalytic site. They become active only after proteolytic removal of this propeptide by a mechanism known as the "cysteine switch" (57), due to a furin-like convertase that cycles between the trans-Golgi network and the plasma membrane (58). Our observation of a blocking effect by a furin inhibitor (Fig. 5) supports the involvement of furin in the LPS-induced shedding of TNF-R. Because furin is a serine protease, the inhibitory effect of TLCK and TPCK (Table II) could be due in part to a nonspecific inhibition of furin.

Because both furin and metalloproteinase are involved in TNF-R cleavage, we examined the influence of combinations of inhibitors of these two classes of enzymes (Fig. 6). We found that the effects of a combination of two metalloproteinase inhibitors were not additive, whereas almost additive effects were observed when the furin inhibitor was combined with one of the three metalloproteinase inhibitors. In particular, a combination of the furin inhibitor with the metalloproteinase inhibitor BB-3103 produced an almost complete inhibition of TNF-R shedding triggered by LPS. This result suggests the existence of two independent shedding pathways, in which a metalloproteinase and a furin are respectively involved.

Concerning the influence of protein kinase inhibitors, little is known about the signaling events involved in the regulation of the activity of sheddases. The cleavage of their substrates is regulated in different cell types by activation of PKC, calcium/calmodulin kinases, or receptor tyrosine kinases. Unexpectedly, we found that among a number of kinases reported to mediate different cellular responses to LPS, many (PKC, cAMP-dependent protein kinase, protein tyrosine kinase, kinases of the Src family, MEK) are not involved in LPS-induced shedding of TNF-R, and only the MAP kinase p38 mediates this effect. It has been reported that the p38 MAPK can be activated by Src-dependent (59) and Src-independent (60) pathways. Our observation that PP2 did not inhibit LPS-induced shedding, whereas SB202190 did, indicates that an Src family independent activation of p38 mediates the shedding of CD120b. This observation is reminiscent to the study of Rizoli et al. (60) who found that shedding of L-selectin induced by hypertonicity is also mediated by Src-independent activation of p38.

The molecular mechanisms by which p38 is involved in the shedding of CD120b remain to be elucidated. We observed in previous studies on the same cell type an LPS-induced shedding of L-selectin (61) which occurred even when the cell nucleus was removed.2 This may suggest that in BMC, LPS-induced sheddings of membrane-associated proteins are independent of the presence of the cell nucleus and, thus, that the p38-dependent shedding of TNF-R is probably not mediated by the activation of a transcription factor. Therefore, p38 could directly or indirectly trigger the activation of an involved enzyme (furin, sheddase) or make available the cleavage site of the substrate (TNF-R). We also observed a reproducible and significant difference in the ability of two p38 inhibitors to block the LPS-induced down-modulation of TNF-R. The concentration of SB203580 required for optimal inhibition of the LPS effect was lower than that of SB202190. This could be due to different sensitivities of p38 isoforms to the inhibitors used.

Our study further addressed the question of the identification of the TNF-{alpha} receptor(s) actually released upon exposure to LPS. The observation that a decreased ability to bind TNF-{alpha} is found in LPS-treated CD120a knockout mice, but not in CD120b knockout mice, shows that the sheddase that is activated by LPS signaling is specific for CD120b. It should be remembered that the two TNF-{alpha} receptors differ significantly in their intracellular signaling domains (62). Most proinflammatory activities of LPS (63) and of soluble TNF-{alpha} (41, 62) are mediated through the CD120a receptor. However, it has been suggested that cell-associated TNF-{alpha} mediates some cellular responses through CD120b. The specific cleavage of CD120b that we observed in BMC is consistent with results obtained by others with monocytes and alveolar macrophages (44) showing that LPS induces mainly the release of CD120b in these cells.

The specificity of the cleavage of CD120b in BMC may have an important physiological relevance. The release of CD120b may desensitize BMC to cell-associated TNF-{alpha} of surrounding cells, and may also augment the clearance of soluble TNF-{alpha} produced in elevated amounts during inflammation. Another function of the cleavage of CD120b in the bone marrow environment could be related to the role ascribed to this receptor in hematopoiesis. CD120b is essential in TNF-{alpha}-mediated inhibition of primitive hematopoietic cells of the bone marrow that are involved in granulopoiesis (64). Therefore, LPS-induced shedding of CD120b from these granulocyte progenitors should enhance granulopoiesis. This can be of uttermost importance insofar as granulocytes are indispensable for efficient host defense against invading microorganisms. This may also explain the well known radioprotective effect of LPS.

In conclusion, the results show that in BMC exposed to low doses of LPS, CD120b is rapidly shed by a mechanism involving the p38 MAPK, furin, and a metalloproteinase that may belong to the family of membrane-type MMPs. What remains unresolved is the identity of this sheddase and the exact mechanism by which it is activated via TLR4.


   FOOTNOTES
 
* This work was supported by Grants 5045 from the Pasteur Institute and 1961 from the CNRS. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

|| To whom correspondence should be addressed. Tel.: 33-169154830; Fax: 33-169853715; E-mail: richard.chaby{at}bbmpc.u-psud.fr.

1 The abbreviations used are: LPS, lipopolysaccharide; TNF-{alpha}, tumor necrosis factor-{alpha}; TNF-R, TNF-{alpha} receptor; BMC, bone marrow cells; PKC, protein kinase C; TLCK, N-tosyl-lysine chloromethyl ketone; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone; MAP, mitogen-activated protein; MAPK, MAP kinase; MEK, MAPK/extracellular signal-regulated kinase kinase; FACS, fluorescence-activated cell sorter; FCS, fetal calf serum; PBS, phosphate-buffered saline; BSA, bovine serum albumin; PMA, phorbol 12-myristate 13-acetate; PGN, peptidoglycan; Bt2cAMP, dibutyryl cyclic AMP; CPT-cAMP, sodium 8-(4-chlorophenylthio)-adenosine-3':5'-cyclic monophosphate; ADAM, a disintegrin and metalloproteinase; TACE, TNF-{alpha}-converting enzyme; TIMPs, tissue inhibitors of matrix metalloproteinases; MMP, matrix metalloproteinase; FcR, Fc receptor; DAVLACK, decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone. Back

2 T. Pedron, R. Girard, and R. Chaby, unpublished observations. Back


   ACKNOWLEDGMENTS
 
We thank Dr. R. W. Carlson (University of Georgia, Athens, GA) for providing the LPSs from Rhizobium species Sin-1, R. galegae, and R. leguminosarum biovar trifolii 24AR. We are indebted to Marina Freudenberg (Max-Planck Institut fur Immunbiologie, Freiburg, Germany) for providing male and female C57BL/10 ScCr mice and to Horst Bluethmann (Hoffmann-La Roche, Switzerland) for providing CD120a–/– and CD120b–/– mice for breeding. We also thank Drs. Arlette Adam, Emanuela Handman, and Salvatore J. Turco for providing PGN, m-LPG, and d-LPG, respectively.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Bodey, G. P., Buckley, M., Sathe, Y. S., and Freireich, E. J. (1966) Ann. Intern. Med. 64, 328–340[Abstract/Free Full Text]
  2. Pedron, T., Girard, R., Turco, S. J., and Chaby, R. (1994) J. Biol. Chem. 269, 2426–2432[Abstract/Free Full Text]
  3. Pedron, T., Girard, R., Inoue, K., Charon, D., and Chaby, R. (1997) Mol. Pharmacol. 52, 692–700[Abstract/Free Full Text]
  4. Pedron, T., Girard, R., and Chaby, R. (2000) FEMS Immunol. Med. Microbiol. 28, 247–256[CrossRef][Medline] [Order article via Infotrieve]
  5. Shepherd, V. L., Abdolrasulnia, R., Garrett, M., and Cowan, H. B. (1990) J. Immunol. 145, 1530–1536[Abstract]
  6. van Lenten, B. J., and Fogelman, A. M. (1992) J. Immunol. 148, 112–116[Abstract]
  7. Bauer, J., Bauer, T. M., Kalb, T., Taga, T., Lengyel, G., Hirano, T., Kishimoto, T., Acs, G., Mayer, L., and Gerok, W. (1989) J. Exp. Med. 170, 1537–1549[Abstract/Free Full Text]
  8. Chen, B. D., Lin, H. S., and Hsu, S. (1983) J. Immunol. 130, 2256–2260[Abstract]
  9. Ding, A. H., Porteu, F., Sanchez, E., and Nathan, C. F. (1990) J. Exp. Med. 171, 715–727[Abstract/Free Full Text]
  10. Chaby, R., Pedron, T., Stutz, P. L., and Girard, R. (1993) J. Immunol. 151, 4476–4485[Abstract]
  11. Beutler, B., Milsark, I. W., and Cerami, A. C. (1985) Science 229, 869–871[Abstract/Free Full Text]
  12. Waage, A., Halstensen, A., and Espevik, T. (1987) Lancet 1, 355–357[CrossRef][Medline] [Order article via Infotrieve]
  13. Peschon, J. J., Slack, J. L., Reddy, P., Stocking, K. L., Sunnarborg, S. W., Lee, D. C., Russell, W. E., Castner, B. J., Johnson, R. S., Fitzner, J. N., Boyce, R. W., Nelson, N., Kozlosky, C. J., Wolfson, M. F., Rauch, C. T., Cerretti, D. P., Paxton, R. J., March, C. J., and Black, R. A. (1998) Science 282, 1281–1284[Abstract/Free Full Text]
  14. Reddy, P., Slack, J. L., Davis, R., Cerretti, D. P., Kozlosky, C. J., Blanton, R. A., Shows, D., Peschon, J. J., and Black, R. A. (2000) J. Biol. Chem. 275, 14608–14614[Abstract/Free Full Text]
  15. Beer, S., Oleszewski, M., Gutwein, P., Geiger, C., and Altevogt, P. (1999) J. Cell Sci. 112, 2667–2675[Abstract]
  16. Hwang, C., Gatanaga, M., Granger, G. A., and Gatanaga, T. (1993) J. Immunol. 151, 5631–5638[Abstract]
  17. Ding, A. H., Sanchez, E., Srimal, S., and Nathan, C. F. (1989) J. Biol. Chem. 264, 3924–3929[Abstract/Free Full Text]
  18. Rothe, J., Lesslauer, W., Lotscher, H., Lang, Y., Koebel, P., Kontgen, F., Althage, A., Zinkernagel, R., Steinmetz, M., and Bluethmann, H. (1993) Nature 364, 798–802[CrossRef][Medline] [Order article via Infotrieve]
  19. Erickson, S. L., de Sauvage, F. J., Kikly, K., Carver-Moore, K., Pitts-Meek, S., Gillett, N., Sheehan, K. C., Schreiber, R. D., Goeddel, D. V., and Moore, M. W. (1994) Nature 372, 560–563[CrossRef][Medline] [Order article via Infotrieve]
  20. Girard, R., Pedron, T., and Chaby, R. (1993) J. Immunol. 150, 4504–4513[Abstract]
  21. Tahri-Jouti, M. A., Mondange, M., Le Dur, A., Auzanneau, F. I., Charon, D., Girard, R., and Chaby, R. (1990) Mol. Immunol. 27, 763–770[CrossRef][Medline] [Order article via Infotrieve]
  22. Tejedor, F., and Ballesta, J. P. (1982) Anal. Biochem. 127, 143–149[CrossRef][Medline] [Order article via Infotrieve]
  23. Pedron, T., Girard, R., and Chaby, R. (1999) Clin. Diagn. Lab. Immunol. 6, 885–890[Abstract/Free Full Text]
  24. Akashi, S., Shimazu, R., Ogata, H., Nagai, Y., Takeda, K., Kimoto, M., and Miyake, K. (2000) J. Immunol. 164, 3471–3475[Abstract/Free Full Text]
  25. Jin, F., Nathan, C. F., and Ding, A. (1999) J. Immunol. 162, 3596–3600[Abstract/Free Full Text]
  26. Gibbs, L. S., Del Vecchio, P. J., and Shaffer, J. B. (1992) Free Radic. Biol. Med. 12, 107–111[CrossRef][Medline] [Order article via Infotrieve]
  27. Haziot, A., Hijiya, N., Gangloff, S. C., Silver, J., and Goyert, S. M. (2001) J. Immunol. 166, 1075–1078[Abstract/Free Full Text]
  28. Poltorak, A., He, X., Smirnova, I., Liu, M. Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler, B. (1998) Science 282, 2085–2088[Abstract/Free Full Text]
  29. Qureshi, S. T., Lariviere, L., Leveque, G., Clermont, S., Moore, K. J., Gros, P., and Malo, D. (1999) J. Exp. Med. 189, 615–625[Abstract/Free Full Text]
  30. Pedron, T., Girard, R., Jeyaretnam, B., Carlson, R. W., and Chaby, R. (2000) Immunology 101, 262–270[CrossRef][Medline] [Order article via Infotrieve]
  31. O'Shea, J. J., Brown, E. J., Gaither, T. A., Takahashi, T., and Frank, M. M. (1985) J. Immunol. 135, 1325–1330[Abstract]
  32. Crowe, P. D., Walter, B. N., Mohler, K. M., Otten-Evans, C., Black, R. A., and Ware, C. F. (1995) J. Exp. Med. 181, 1205–1210[Abstract/Free Full Text]
  33. Porteu, F., Brockhaus, M., Wallach, D., Engelmann, H., and Nathan, C. F. (1991) J. Biol. Chem. 266, 18846–18853[Abstract/Free Full Text]
  34. Pedron, T., Girard, R., and Chaby, R. (2000) Biochem. Pharmacol. 60, 1837–1843[CrossRef][Medline] [Order article via Infotrieve]
  35. Lowell, C. A., and Berton, G. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 7580–7584[Abstract/Free Full Text]
  36. Williams, L. M., and Ridley, A. J. (2000) J. Immunol. 164, 2028–2036[Abstract/Free Full Text]
  37. Orlicek, S. L., Hanke, J. H., and English, B. K. (1999) Shock 12, 350–354[Medline] [Order article via Infotrieve]
  38. Meng, F., and Lowell, C. A. (1997) J. Exp. Med. 185, 1661–1670[Abstract/Free Full Text]
  39. Zhu, X., Kim, J. L., Newcomb, J. R., Rose, P. E., Stover, D. R., Toledo, L. M., Zhao, H., and Morgenstern, K. A. (1999) Struct. Fold Des. 7, 651–661[Medline] [Order article via Infotrieve]
  40. Mullberg, J., Rauch, C. T., Wolfson, M. F., Castner, B., Fitzner, J. N., Otten-Evans, C., Mohler, K. M., Cosman, D., and Black, R. A. (1997) FEBS Lett. 401, 235–238[CrossRef][Medline] [Order article via Infotrieve]
  41. Takakuwa, T., Knopf, H. P., Sing, A., Carsetti, R., Galanos, C., and Freudenberg, M. A. (1996) Eur. J. Immunol. 26, 2686–2692[Medline] [Order article via Infotrieve]
  42. Carpenter, A., Evans, T. J., Buurman, W. A., Bemelmans, M. H., Moyes, D., and Cohen, J. (1995) J. Immunol. 155, 2005–2012[Abstract]
  43. Herman, C., and Chernajovsky, Y. (1998) J. Immunol. 160, 2478–2487[Abstract/Free Full Text]
  44. Galve-de Rochemonteix, B., Nicod, L. P., and Dayer, J. M. (1996) Am. J. Respir. Cell Mol. Biol. 14, 279–287[Abstract]
  45. Doedens, J. R., and Black, R. A. (2000) J. Biol. Chem. 275, 14598–14607[Abstract/Free Full Text]
  46. Black, R. A., Rauch, C. T., Kozlosky, C. J., Peschon, J. J., Slack, J. L., Wolfson, M. F., Castner, B. J., Stocking, K. L., Reddy, P., Srinivasan, S., Nelson, N., Boiani, N., Schooley, K. A., Gerhart, M., Davis, R., Fitzner, J. N., Johnson, R. S., Paxton, R. J., March, C. J., and Cerretti, D. P. (1997) Nature 385, 729–733[CrossRef][Medline] [Order article via Infotrieve]
  47. Pan, D., and Rubin, G. M. (1997) Cell 90, 271–280[CrossRef][Medline] [Order article via Infotrieve]
  48. Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, H., Arribas, J., Blackburn, R. K., Weskamp, G., Tempst, P., and Blobel, C. P. (1999) J. Biol. Chem. 274, 3531–3540[Abstract/Free Full Text]
  49. Gearing, A. J., Beckett, P., Christodoulou, M., Churchill, M., Clements, J., Davidson, A. H., Drummond, A. H., Galloway, W. A., Gilbert, R., Gordon, J. L., Leber, T. M., Mangan, M., Miller, K., Nayee, P., Owen, K., Patel, S., Thomas, W., Wells, G., Wood, L. M., and Wooley, K. (1994) Nature 370, 555–557[CrossRef][Medline] [Order article via Infotrieve]
  50. Hooper, N. M., Karran, E. H., and Turner, A. J. (1997) Biochem. J. 321, 265–279
  51. Merlos-Suarez, A., Fernandez-Larrea, J., Reddy, P., Baselga, J., and Arribas, J. (1998) J. Biol. Chem. 273, 24955–24962[Abstract/Free Full Text]
  52. Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., and Baselga, J. (1999) Cancer Res. 59, 1196–1201[Abstract/Free Full Text]
  53. Sternlicht, M. D., and Werb, Z. (2001) Annu. Rev. Cell Dev. Biol. 17, 463–516[CrossRef][Medline] [Order article via Infotrieve]
  54. Amour, A., Knight, C. G., Webster, A., Slocombe, P. M., Stephens, P. E., Knauper, V., Docherty, A. J., and Murphy, G. (2000) FEBS Lett. 473, 275–279[CrossRef][Medline] [Order article via Infotrieve]
  55. Amour, A., Slocombe, P. M., Webster, A., Butler, M., Knight, C. G., Smith, B. J., Stephens, P. E., Shelley, C., Hutton, M., Knauper, V., Docherty, A. J., and Murphy, G. (1998) FEBS Lett. 435, 39–44[CrossRef][Medline] [Order article via Infotrieve]
  56. English, W. R., Velasco, G., Stracke, J. O., Knauper, V., and Murphy, G. (2001) FEBS Lett. 491, 137–142[CrossRef][Medline] [Order article via Infotrieve]
  57. Birkedal-Hansen, H. (1995) Curr. Opin. Cell Biol. 7, 728–735[CrossRef][Medline] [Order article via Infotrieve]
  58. Sato, H., Kinoshita, T., Takino, T., Nakayama, K., and Seiki, M. (1996) FEBS Lett. 393, 101–104[CrossRef][Medline] [Order article via Infotrieve]
  59. Mocsai, A., Jakus, Z., Vantus, T., Berton, G., Lowell, C. A., and Ligeti, E. (2000) J. Immunol. 164, 4321–4331[Abstract/Free Full Text]
  60. Rizoli, S. B., Rotstein, O. D., and Kapus, A. (1999) J. Biol. Chem. 274, 22072–22080[Abstract/Free Full Text]
  61. Pedron, T., Girard, R., and Chaby, R. (2001) Infect. Immun. 69, 4287–4294[Abstract/Free Full Text]
  62. Aggarwal, B. B., Samanta, A., and Feldmann, M. (2000) in Cytokine Reference. A Compendium of Cytokines and Other Mediators of Host Defense (Durum, S. K., Hirano, T., Vilcek, J., and Nicola, N. A., eds) Vol. 2, pp. 1619–1632, Academic Press, San Diego
  63. Nowak, M., Gaines, G. C., Rosenberg, J., Minter, R., Bahjat, F. R., Rectenwald, J., MacKay, S. L., Edwards, C. K., III, and Moldawer, L. L. (2000) Am. J. Physiol. 278, R1202–R1209
  64. Jacobsen, F. W., Rothe, M., Rusten, L., Goeddel, D. V., Smeland, E. B., Veiby, O. P., Slordal, L., and Jacobsen, S. E. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10695–10699[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
H. P. Jia, D. C. Look, P. Tan, L. Shi, M. Hickey, L. Gakhar, M. C. Chappell, C. Wohlford-Lenane, and P. B. McCray Jr
Ectodomain shedding of angiotensin converting enzyme 2 in human airway epithelia
Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L84 - L96.
[Abstract] [Full Text] [PDF]

Home page
 J ANIM SCIHome page
N. K. Gabler and M. E. Spurlock
Integrating the immune system with the regulation of growth and efficiency
J Anim Sci, April 1, 2008; 86(14_suppl): E64 - E74.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Paland, L. Bohme, R. K. Gurumurthy, A. Maurer, A. J. Szczepek, and T. Rudel
Reduced Display of Tumor Necrosis Factor Receptor I at the Host Cell Surface Supports Infection with Chlamydia trachomatis
J. Biol. Chem., March 7, 2008; 283(10): 6438 - 6448.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
L. Wang, R.-F. Chen, J.-W. Liu, H.-R. Yu, H.-C. Kuo, and K. D. Yang
Implications of Dynamic Changes among Tumor Necrosis Factor-{alpha} (TNF-{alpha}), Membrane TNF Receptor, and Soluble TNF Receptor Levels in Regard to the Severity of Dengue Infection
Am J Trop Med Hyg, August 1, 2007; 77(2): 297 - 302.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
278/23/20555    most recent
M203551200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pedron, T.
Right arrow Articles by Chaby, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pedron, T.
Right arrow Articles by Chaby, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2003 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement